American CryoStem Corporation Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2022

American CryoStem Corporation is a biotechnology company. The Company has developed adipose tissue-derived technologies (Adult Stem Cells) for the fields of regenerative and personalized medicine. Its technologies are the basis for the chemistry, manufacturing, and controls (cGMP Manufacturing) of its ATCell autologous cellular therapy product for use in clinical investigations for biologic license applications with the United States Food and Drug Administration (FDA). The Company has developed and refined its pipeline around its cellular product, ATCell, for clinical therapeutic use. The Company’s ATCELL cell lines are cultured in its patented ACSelerate cell culture media. Its CELLECT service is the required platform for the collection and transportation of live adipose tissue samples to its processing facility. Its ACSelerate cell culture media products are manufactured using patented cell culture media for growing human stromal cells. The Company also includes ATGRAFT services.